Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

Stock futures edged lower on Monday due to trade war concerns and the upcoming 25% levy on non-US cars. President Trump has ...

Vaxcyte plunges 56% even though its VAX-24 pneumonia vaccine shows positive phase two results in infants. Read more here.

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

Vaxcyte (PCVX) shared topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, ...

(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today shared positive topline results ...

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect ...

The newest formulations, PCV15 (Vaxneuvance) and PCV 20 (Prevnar 20), were approved in 2022 and 2023 ... but it's only ...

Prevnar revenues were in line with the Zacks ... Paxlovid revenues were $727 million in the quarter against negative $3.2 billion in the year-ago quarter. Paxlovid revenues beat the Zacks ...